NEPTAZANE Drug Patent Profile
✉ Email this page to a colleague
When do Neptazane patents expire, and when can generic versions of Neptazane launch?
Neptazane is a drug marketed by Lederle and is included in one NDA.
The generic ingredient in NEPTAZANE is methazolamide. There are seven drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the methazolamide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Neptazane
A generic version of NEPTAZANE was approved as methazolamide by ANI PHARMS on June 30th, 1993.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for NEPTAZANE?
- What are the global sales for NEPTAZANE?
- What is Average Wholesale Price for NEPTAZANE?
Summary for NEPTAZANE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 117 |
| Clinical Trials: | 3 |
| Patent Applications: | 3,737 |
| DailyMed Link: | NEPTAZANE at DailyMed |
Recent Clinical Trials for NEPTAZANE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Miami | Phase 3 |
| National Eye Institute (NEI) | Phase 3 |
| Colorado State University | Phase 1/Phase 2 |
US Patents and Regulatory Information for NEPTAZANE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lederle | NEPTAZANE | methazolamide | TABLET;ORAL | 011721-002 | Nov 25, 1991 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Lederle | NEPTAZANE | methazolamide | TABLET;ORAL | 011721-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
